CT7439

PreclinicalSmall molecule

CCarrick Therapeutics Limited

CT7439 is one of 5 small molecule programs targeting Solid Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid MalignanciesRecruiting

Solid MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Solid Malignancies

#DrugCompanyPhaseTrials

Dostarlimab

Incyte

Phase 2

1 2

Jakafi

Incyte

Phase 2

1 3

Imfinzi

AstraZeneca

Phase 1

1 4

Imjudo

AstraZeneca

Phase 1

1 5

CT7439

CCarrick Therapeutics Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Solid Malignancies

NCT06600789

Clinical

Trials by Indication[1]

Solid Malignancies1 trial

A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies

Recruiting·CCarrick Therapeutics Limited·Preclinical·NCT06600789·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CT7439. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CT7439 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CT7439. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Carrick Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCarrick Therapeutics Limited

CT7439

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News